Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 5, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share movements on August 31, 2005, executed by the SmithKline Beecham Employee Benefit Trust ("the Trust") on behalf of participants in the GlaxoSmithKline Annual Investment Plan:
- Shares Sold: 4,037 Ordinary shares were sold at a price of GBP 13.36 per share.
- Shares Transferred: 9,098 Ordinary shares were transferred from the Trust to a participant.
Director Mr. J Heslop is noted as having an interest in the shares held in the fund, consistent with other non-US employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of shares sold (4,037) and transferred (9,098) by the Employee Benefit Trust on August 31, 2005.
- Confirm the transaction price of GBP 13.36 per share for the sold portion.
- Note that Director Mr. J Heslop's interest is indirect through the discretionary fund for non-US employees.
- Understand that this filing contains no financial performance metrics or strategic outlook.